Blog
RSS FeedPosted by Michael Wonder on 23 Oct 2020
TLV reconsiders the subsidy of Rinvoq
23 October 2020 - TLV starts a reconsideration of the current subsidy status for Rinvoq. ...
Posted by Michael Wonder on 12 Oct 2020
Ambrisentan, diazepam and dexamethasone new exchange groups
9 October 2020 - From November, ambrisentan 5 mg & 10 mg tablets, diazepam,10 mg tablets and dexamethasone 1 mg/mL ...
Posted by Michael Wonder on 30 Sep 2020
Saxenda is not included in the high-cost protection
29 September 2020 - Liraglutide (Saxenda), which is intended for weight control in adult patients with obesity or are overweight, ...
Posted by Michael Wonder on 29 Sep 2020
Epidyolex oral solution is not included in the high-cost protection
29 September 2020 - On 28 September 2020, it was decided that Epidyolex is not included in the high-cost protection. ...
Posted by Michael Wonder on 23 Sep 2020
More patients will have access to medicines within the high-cost protection
23 September 2020 - From 2 June 2020, patients who pick up prescription drugs at pharmacies can switch to an ...
Posted by Michael Wonder on 21 Sep 2020
The next step in TLV's review of pricing of stock preparations
21 September 2020 - In the process of reviewing the pricing of stock preparations, TLV contacted the pharmaceutical companies concerned during ...
Posted by Michael Wonder on 06 Sep 2020
Venclyxto in combination with obinutuzumab is included in the high-cost protection with limitation
28 August 2020 - Venclyxto (venetoclax) is already included in the high-cost protection with limited subsidy. ...
Posted by Michael Wonder on 03 Sep 2020
Tolak is included in the high-cost protection
2 September 2020 - Tolak, a topical treatment for adults with non-hyperkeratotic and non-hypertrophic actinic keratosis (Olsen grade I and II) ...
Posted by Michael Wonder on 02 Sep 2020
Namuscla is granted a temporary subsidy
1 September 2020 - TLV has decided that Namuscla 167 mg capsules will be included in the high-cost protection until ...
Posted by Michael Wonder on 01 Sep 2020
Emgality is included in the high-cost protection with limitation
1 September 2020 - Emgality (galcanezumab), which is a preventive drug treatment for migraines, is included in the high-cost protection with ...
Posted by Michael Wonder on 01 Sep 2020
New formulation of Entyvio is included in the high-cost protection with limitation
1 September 2020 - Entyvio (vedolizumab) in the new dosage form of a solution for subcutaneous injection is included in the ...
Posted by Michael Wonder on 31 Aug 2020
A new biosimilar to NovoRapid is included in the high-cost protection
28 August 2020 - Insulin aspart Sanofi (insulin aspart) solution for injection for the treatment of diabetes is included in ...
Posted by Michael Wonder on 29 Aug 2020
Rybelsus is included in the high-cost protection with restriction
28 August 2020 - Rybelsus (semaglutide) is intended for the treatment of adults with type 2 diabetes in adults as the ...
Posted by Michael Wonder on 13 Jul 2020
EUnetHTA is extended for one year and focuses on COVID-19
9 July 2020 - The European project EUnetHTA, in which TLV, SBU and the Swedish Medicines Agency are Swedish partners, ...
Posted by Michael Wonder on 08 Jul 2020
TLV is reviewing the subsidy of SGLT-2 inhibitors
8 July 2020 - TLV has started a review of subsidy restrictions for the SGLT-2 inhibitors. ...